stockrow
Saturday 7 November 2026
Export MNPR’s income statement to Excel — free account
Monopar Therapeutics Inc.
MNPR Healthcare Biotechnology
- EPS
- −77.1%
- Free cash flow
- −201.4%
Quarter to June 2026, against a year earlier
71.42
4.20
+6.25%
Follow MNPR
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (19.50%) | (15.86%) | (14.22%) | (26.54%) |
+8 more TTM periods Free account |
|
| (18.90%) | (15.52%) | (13.65%) | (25.88%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(13.65%) | (11.08%) | (9.96%) | (13.74%) | |
Free Cash Flow per Share |
(1.43) | (1.17) | (1.65) | (1.52) | |
Free Cash Flow |
(12.18) | (10.01) | (12.20) | (10.83) | |
| Other line items | |||||
Cash ROIC |
(4.59%) | (3.67%) | (4.39%) | (3.80%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.68 | 0.67 | 0.89 | 0.56 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | — | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.43) | (1.17) | (1.65) | (1.52) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates